IGF2AS Inhibitors

The chemicals listed above are not classified as IGF2AS Inhibitors due to the uncertainty regarding the identity of IGF2AS. However, these compounds are known to modulate the insulin-like growth factor signaling pathway, which includes both IGF-1 and IGF-2 mediated processes. The insulin-like growth factor signaling pathway is involved in various cellular processes such as cell proliferation, differentiation, and survival. The pathway predominantly involves the interaction of IGF-1 and IGF-2 with their receptor, IGF-1R, which also binds to insulin receptors.The compounds that target IGF-1R can indirectly influence IGF-2 signaling because IGF-2 shares the same receptor.

XL228 and Nordihydroguaiaretic acid represent broader kinase inhibitors and lipoxygenase inhibitors, respectively, that can impact IGF signaling more broadly. CP-751,871, while a biological molecule (antibody), is included for completeness as it binds IGF-1R and thus may affect IGF-2 signaling as well. Mecasermin is a recombinant form of IIGF-1, which could compete with IGF-2 for receptor binding sites, potentially modulating the activity of IGF-2.

The chemical class described above involves inhibitors that target the IGF-1/IGF-2 signaling pathways. Most of the inhibitors are small molecules that interact with the IGF-1 receptor, which plays a crucial role in mediating the effects of IGF-2 due to the high affinity of IGF-2 for the IGF-1R. This receptor is a tyrosine kinase, and its activation triggers a cascade of intracellular events leading to cellular proliferation and survival. By inhibiting this receptor, the chemicals indirectly disrupt IGF-2 signaling, which shares the same receptor and downstream pathways.